These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 24154874)

  • 41. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer.
    Kan CW; Hahn MA; Gard GB; Maidens J; Huh JY; Marsh DJ; Howell VM
    BMC Cancer; 2012 Dec; 12():627. PubMed ID: 23272653
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
    Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential gene expression analysis of ovarian cancer in a population isolate.
    Grazio D; Pichler I; Fuchsberger C; Zolezzi F; Guarnieri P; Heidegger H; Scherer A; Engl B; Messini S; Egarter-Vigl E; Pramstaller PP
    Eur J Gynaecol Oncol; 2008; 29(4):357-63. PubMed ID: 18714569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The immunohistochemical features of ovarian serous adenocarcinoma cells, which determine a disease course and survival rates in patients].
    Pozharissky KM; Raskin GA; Vinokurov VL; Yurkova LE; Mukhina MS
    Arkh Patol; 2015; 77(1):38-40. PubMed ID: 25868367
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer.
    Elattar A; Warburton KG; Mukhopadhyay A; Freer RM; Shaheen F; Cross P; Plummer ER; Robson CN; Edmondson RJ
    Gynecol Oncol; 2012 Jan; 124(1):142-7. PubMed ID: 22001143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human APOBEC3B promotes tumor development in vivo including signature mutations and metastases.
    Durfee C; Temiz NA; Levin-Klein R; Argyris PP; Alsøe L; Carracedo S; Alonso de la Vega A; Proehl J; Holzhauer AM; Seeman ZJ; Liu X; Lin YT; Vogel RI; Sotillo R; Nilsen H; Harris RS
    Cell Rep Med; 2023 Oct; 4(10):101211. PubMed ID: 37797615
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
    Marquez RT; Baggerly KA; Patterson AP; Liu J; Broaddus R; Frumovitz M; Atkinson EN; Smith DI; Hartmann L; Fishman D; Berchuck A; Whitaker R; Gershenson DM; Mills GB; Bast RC; Lu KH
    Clin Cancer Res; 2005 Sep; 11(17):6116-26. PubMed ID: 16144910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B.
    Akre MK; Starrett GJ; Quist JS; Temiz NA; Carpenter MA; Tutt AN; Grigoriadis A; Harris RS
    PLoS One; 2016; 11(5):e0155391. PubMed ID: 27163364
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
    Angarita AM; Cholakian D; Fader AN
    Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Involvement of APOBEC3B in mutation induction by irradiation.
    Saito Y; Miura H; Takahashi N; Kuwahara Y; Yamamoto Y; Fukumoto M; Yamamoto F
    J Radiat Res; 2020 Nov; 61(6):819-827. PubMed ID: 32880638
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CTD-2020K17.1, a Novel Long Non-Coding RNA, Promotes Migration, Invasion, and Proliferation of Serous Ovarian Cancer Cells In Vitro.
    Zhu L; Guo Q; Lu X; Zhao J; Shi J; Wang Z; Zhou X
    Med Sci Monit; 2018 Mar; 24():1329-1339. PubMed ID: 29504606
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer.
    Harris RS
    Breast Cancer Res; 2015 Jan; 17(1):8. PubMed ID: 25848704
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B.
    Vieira VC; Leonard B; White EA; Starrett GJ; Temiz NA; Lorenz LD; Lee D; Soares MA; Lambert PF; Howley PM; Harris RS
    mBio; 2014 Dec; 5(6):. PubMed ID: 25538195
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
    Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Popa I; Bachvarov D
    Int J Oncol; 2017 Dec; 51(6):1887-1897. PubMed ID: 29039611
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Tumor-Promoting Phorbol Ester Causes a Large Increase in APOBEC3A Expression and a Moderate Increase in APOBEC3B Expression in a Normal Human Keratinocyte Cell Line without Increasing Genomic Uracils.
    Siriwardena SU; Perera MLW; Senevirathne V; Stewart J; Bhagwat AS
    Mol Cell Biol; 2019 Jan; 39(1):. PubMed ID: 30348839
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
    Yang M; Xie X; Ding Y
    Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer.
    Zhang Y; Delahanty R; Guo X; Zheng W; Long J
    Hum Genomics; 2015 Dec; 9():34. PubMed ID: 26682542
    [TBL] [Abstract][Full Text] [Related]  

  • 59. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.
    Wang S; Jia M; He Z; Liu XS
    Oncogene; 2018 Jul; 37(29):3924-3936. PubMed ID: 29695832
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mesoscale DNA features impact APOBEC3A and APOBEC3B deaminase activity and shape tumor mutational landscapes.
    Sanchez A; Ortega P; Sakhtemani R; Manjunath L; Oh S; Bournique E; Becker A; Kim K; Durfee C; Temiz NA; Chen XS; Harris RS; Lawrence MS; Buisson R
    Nat Commun; 2024 Mar; 15(1):2370. PubMed ID: 38499542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.